Home > Boards > US Listed > Medical - Healthcare > Pfenex Inc. (PFNX)

And here's the reason

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Paullee Member Profile
 
Followed By 15
Posts 2,278
Boards Moderated 0
Alias Born 11/25/03
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 5/11/2020 4:56:11 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/7/2020 5:07:02 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 5/7/2020 5:04:47 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/7/2020 4:16:29 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/7/2020 4:09:21 PM
Pfenex Reports First Quarter 2020 Results and Provides Business Update GlobeNewswire Inc. - 5/7/2020 4:05:10 PM
Pfenex to Announce First Quarter 2020 Financial Results on May 7 GlobeNewswire Inc. - 4/24/2020 4:05:10 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/23/2020 8:01:41 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/14/2020 5:18:23 PM
Pfenex Announces FDA Requests Additional Comparative Use Human Factors Data in Experienced Users in order to Complete PF708 T... GlobeNewswire Inc. - 4/14/2020 5:04:52 PM
Confidential Treatment Order (ct Order) Edgar (US Regulatory) - 4/14/2020 11:01:26 AM
Confidential Treatment Order (ct Order) Edgar (US Regulatory) - 4/10/2020 4:33:26 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/1/2020 4:55:51 PM
Annual Report (10-k) Edgar (US Regulatory) - 3/11/2020 4:33:45 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/11/2020 4:13:10 PM
Pfenex Reports Fourth Quarter and Full Year 2019 Results and Provides Business Update GlobeNewswire Inc. - 3/11/2020 4:05:10 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/3/2020 6:05:21 PM
Pfenex to Announce Fourth Quarter and Year-End 2019 Financial Results on March 11 GlobeNewswire Inc. - 2/26/2020 5:03:26 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2020 6:01:05 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/13/2020 2:51:36 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/12/2020 2:51:20 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/5/2020 2:45:05 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/5/2020 12:18:01 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/4/2020 8:01:46 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/16/2020 4:18:20 PM
Paullee   Wednesday, 12/18/19 08:12:01 AM
Re: None
Post # of 49 
And here's the reason
Pfenex Earns $15 Million Development Milestone Under its Development and License Agreement With Jazz Pharmaceuticals
GlobeNewswire GlobeNewswire•December 18, 2019
SAN DIEGO, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) today announced that it has earned a $15 million development milestone under its development and license agreement with Jazz Pharmaceuticals plc. The milestone is associated with process development activities for PF745, a long-acting Erwinia asparaginase.

“We are very pleased with the rapid progression of the PF745 program and we believe the Jazz collaboration, overall, further validates the versatility of our proprietary protein expression platform and the quality of our development capabilities,” said Eef Schimmelpennink, Chief Executive Officer of Pfenex. “Additionally, we are excited about Jazz’s recent announcement that the lead product in our partnership, PF743 (JZP-458), is expected to begin recruiting patients into the pivotal Phase 2/3 clinical study as early as this month.”

Under the terms of the development and license agreement, Pfenex is eligible to receive an aggregate total of up to $224.5 million in development and sales milestones, of which $162.5 million is still eligible to be received by Pfenex, including up to $3.5 million for development milestones, $34 million in regulatory milestones and $125 million in sales milestones. Pfenex may also be eligible to receive tiered royalties based on worldwide sales of any products resulting from the collaboration.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist